ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.
Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)
A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry
Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds
Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures.
Synergistic Interactions for Improved Cancer Treatment
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.
Muramyl Dipeptide as a Therapeutic Agent for Inflammation
Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites
Malaria is one of the worlds deadliest infectious diseases, causing an estimated 249 million cases and 608,000 deaths annually, with children in the regions of Africa and South Asia being most vulnerable. Approx 2,000 cases of malaria are reported in the United States each year, by travelers from malaria-risk countries. Malaria is a mosquito-borne parasitic disease transmitted through the bite of infected female mosquitoes, which introduces Plasmodium sporozoites into the bloodstream of the human host.
Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research
Fluorinated MU-Opioid Receptor Agonists
Summary:
Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.
Description of Technology:
Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.